Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Our study on the prognosis of small TNBCs is out in NPJ Journals Breast. Among 8601 pts with stage I TNBC in SEER, we found excellent 5-year outcomes, with a significant BCSS benefit for chemo in pT1c. Benefit less clear in tumors ≤1cm: biomarkers needed! ”
Read further.
Source: Paolo Tarantino/X